menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Treating ATTR-CM with a Novel Therapeutic Approach: Understanding the ATTRibutes to Success

Join our experts as they discuss the evolving understanding of ATTR-CM and the latest clinical evidence for this now-treatable condition.

Live Meeting
1.50 available credits
Information
November 11, 2023
19:30 - 21:00 EST
Four Points by Sheraton Philadelphia City Center
Jefferson Room, 1201 Race St, Philadelphia, Pennsylvania, United States
ReachMD Healthcare Image
Details
Presenters
Related
Comments
  • Overview

    Once considered rare and untreatable, amyloid transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM) has increased in incidence over the last decade and is now a treatable condition. This transformation is due, in part, to our understanding of the biology of the disease and recognition of comorbid or co-occurring conditions in patients with both cardiac and noncardiac amyloidosis. In an open discussion, chairperson Martha Grogan, MD, and faculty members Marianna Fontana, MD, and Nitasha Sarswat, MD, will provide an updated review of the disease state. They will shed light on our shifting understanding of the mechanism of the disease, discuss the pathogenic and protective genetic variants, and share evidence from clinical trials that are impacting the evolving treatment landscape.

  • Program Schedule*

    7:15 pm – 7:30 pm:          Registration and Dinner

    7:30 pm – 7:37 pm:          Welcome and Introductions

    7:37 pm – 7:45 pm:          Updates to ATTR-CM Disease State

    7:45 pm – 7:50 pm:          Change in ATTR-CM Management Strategies

    7:50 pm – 7:55 pm:          ATTR-CM Mechanism of Action

    7:55 pm – 8:03 pm:          ATTR-CM Statistical Review

    8:03 pm – 8:13 pm:          ATTR-CM Clinical Data Review

    8:13 pm – 8:48 pm:          Faculty Discussion and Question and Answer Session

    8:48 pm – 9:00 pm:          Closing Remarks

    *Subject to change

    This event is not part of the official Scientific Sessions 2023 as planned by the American Heart Association Committee on Scientific Sessions Program.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Martha Grogan, MD, FACP, FACC
    Director, Cardiac Amyloid Clinic
    Associate Professor of Medicine
    Department of Cardiovascular Diseases
    Mayo Clinic
    Rochester, MN

    Consulting Fees: AstraZeneca, Janssen, Novo Nordisk, Prothena
    Research: Alnylam, BridgeBio, Eidos, Janssen, Novo Nordisk, Pfizer

    Faculty:
    Marianna Fontana, MD
    Director of the UCL CMR Unit, Royal Free Hospital
    Professor of Cardiology and Honorary Consultant Cardiologist
    National Amyloidosis Centre, Division of Medicine
    University College London
    London, UK

    Consulting Fees: Akcea, Alexion, Alnylam, AstraZeneca, Attralus, Intellia, Ionis, Janssen, Novo Nordisk, Pfizer, Prothena
    Research: Alnylam, Eidos, Pfizer

    Nitasha Sarswat, MD
    Director, Infiltrative Cardiomyopathy Program
    Advanced Heart Failure, Mechanical Circulatory Support and Transplantation
    University of Chicago Hospital
    Chicago, IL

    Consulting Fees: Alnylam, BridgeBio, Pfizer
    Research: Pfizer

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Howard Green has nothing to disclose.
    • Andrea Mathis has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Mario Trucillo, PhD, MS, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the pathophysiology and genetic variation of amyloid transthyretin amyloidosis with cardiomyopathy (ATTR-CM)
    • Discuss the clinical manifestations and diagnosis of ATTR-CM
    • Compare the treatment options available for patients with ATTR-CM
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, cardiology nurse practitioners, physician associates, and nurses.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from BridgeBio.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • ADA Statement

    Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

Facebook Comments

Details
Presenters
Related
Comments
Recommended
  • Overview

    Once considered rare and untreatable, amyloid transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM) has increased in incidence over the last decade and is now a treatable condition. This transformation is due, in part, to our understanding of the biology of the disease and recognition of comorbid or co-occurring conditions in patients with both cardiac and noncardiac amyloidosis. In an open discussion, chairperson Martha Grogan, MD, and faculty members Marianna Fontana, MD, and Nitasha Sarswat, MD, will provide an updated review of the disease state. They will shed light on our shifting understanding of the mechanism of the disease, discuss the pathogenic and protective genetic variants, and share evidence from clinical trials that are impacting the evolving treatment landscape.

  • Program Schedule*

    7:15 pm – 7:30 pm:          Registration and Dinner

    7:30 pm – 7:37 pm:          Welcome and Introductions

    7:37 pm – 7:45 pm:          Updates to ATTR-CM Disease State

    7:45 pm – 7:50 pm:          Change in ATTR-CM Management Strategies

    7:50 pm – 7:55 pm:          ATTR-CM Mechanism of Action

    7:55 pm – 8:03 pm:          ATTR-CM Statistical Review

    8:03 pm – 8:13 pm:          ATTR-CM Clinical Data Review

    8:13 pm – 8:48 pm:          Faculty Discussion and Question and Answer Session

    8:48 pm – 9:00 pm:          Closing Remarks

    *Subject to change

    This event is not part of the official Scientific Sessions 2023 as planned by the American Heart Association Committee on Scientific Sessions Program.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Martha Grogan, MD, FACP, FACC
    Director, Cardiac Amyloid Clinic
    Associate Professor of Medicine
    Department of Cardiovascular Diseases
    Mayo Clinic
    Rochester, MN

    Consulting Fees: AstraZeneca, Janssen, Novo Nordisk, Prothena
    Research: Alnylam, BridgeBio, Eidos, Janssen, Novo Nordisk, Pfizer

    Faculty:
    Marianna Fontana, MD
    Director of the UCL CMR Unit, Royal Free Hospital
    Professor of Cardiology and Honorary Consultant Cardiologist
    National Amyloidosis Centre, Division of Medicine
    University College London
    London, UK

    Consulting Fees: Akcea, Alexion, Alnylam, AstraZeneca, Attralus, Intellia, Ionis, Janssen, Novo Nordisk, Pfizer, Prothena
    Research: Alnylam, Eidos, Pfizer

    Nitasha Sarswat, MD
    Director, Infiltrative Cardiomyopathy Program
    Advanced Heart Failure, Mechanical Circulatory Support and Transplantation
    University of Chicago Hospital
    Chicago, IL

    Consulting Fees: Alnylam, BridgeBio, Pfizer
    Research: Pfizer

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Howard Green has nothing to disclose.
    • Andrea Mathis has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Mario Trucillo, PhD, MS, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the pathophysiology and genetic variation of amyloid transthyretin amyloidosis with cardiomyopathy (ATTR-CM)
    • Discuss the clinical manifestations and diagnosis of ATTR-CM
    • Compare the treatment options available for patients with ATTR-CM
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, cardiology nurse practitioners, physician associates, and nurses.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from BridgeBio.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • ADA Statement

    Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

Facebook Comments

Schedule19 Jul 2024